Johnson & Johnson
Annual return '25
+17.7%
SPY '25
+17.7%
Alpha
-0.1ptsvs SPY
Invested
$652.4M
Holdings
16
Trades YTD
0
Performance · Fund vs SPY
Cumulative return · quarterly snapshotsCoverage 100%. 4 quarters of 2025 measured against SPY adj-close benchmark.
Top holdings · current snapshot
Source: 13F-HR01
$PTGX
Protagonist Therapeutics Inc.
Q4 2024: New position (2.45M shares)
39.6%
02
$NBTX
Nanobiotix S.A.
Q4 2024: New position (5.62M shares)
26.6%
03
$MGTX
MeiraGTx Holdings plc
Q4 2024: New position (6.64M shares)
8.8%
04
$RAPP
Rapport Therapeutics, Inc.
Q3 2025: Sold 28.6% (2.50M → 1.78M shares)
8.6%
05
$CVRX
CVRx, Inc.
Q4 2025: Sold 1.9% (4.10M → 4.02M shares)
5.8%
06
$CTNM
Contineum Therapeutics Inc.
Q4 2024: New position (1.98M shares)
4.0%
07
$LEGN
Legend Biotech Corporation
Q4 2024: New position (814.6k shares)
2.3%
08
$XNCR
Xencor, Inc.
Q4 2024: New position (748.1k shares)
1.4%
09
$PRCT
Procept BioRobotics Corporation
Q4 2024: New position (357.9k shares)
1.4%
10
$FATE
Fate Therapeutics, Inc.
Q4 2024: New position (3.38M shares)
0.6%
Recent trades · Last 90 days
No Form 4 / 13D / 13G trade events on file in the recent window. 13F filers report position snapshots quarterly rather than per-trade events, so this section is most useful for managers who also file Form 4 or 13D/G.
Convergence · Pattern Engine ships in v1.1
30-day windowIn development
Convergence participation lands with the Pattern Engine.
Once the Pattern Engine ships, this section will list every active convergence event this fund is named in — with the other named funds, the Congress members on the same name, and combined position size.
Source data: SEC EDGAR · 13F-HR filings · Performance through 2025-12-31 · Last refreshed 08:26 UTC.